Agenus presented clinical study data on botensilimab and balstilimab at the ESMO Congress in Berlin on July 26, 2025.
1 report, 1 independent
Updated Jul 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agenus presented clinical study data on botensilimab and balstilimab at the ESMO Congress in Berlin on July 26, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Agenus
biotechnology company
Nothing else this week.
-
European Society for Medical Oncology
Professional organisation
Related events
- AstraZeneca presented trial results at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Bristol-Myers Squibb presented clinical data at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.
Coverage
Newest first; wire copies grouped- Business WireAgenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 LEXINGTON, Mass., July 25, 2025-